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Objective: The burden of clinically relevant noncoronary atherosclerotic occlusive disease in patients with abdominal
aortic aneurysms (AAAs) is poorly defined. Furthermore, the cost-effectiveness of routine versus selective preoperative
noninvasive examination of the carotid and lower extremity arterial beds has not been established in patients who
undergo elective AAA repair.
Methods: Diagnostic vascular laboratory study results were reviewed in 206 patients who underwent evaluation before
AAA repair from 1994 to 1998. The patients underwent routine preoperative carotid duplex scan examinations and lower
extremity Doppler scan arterial studies with ankle-brachial index (ABI) determinations. The medical records were
reviewed for the identification of clinical evidence consistent with cerebrovascular or lower extremity arterial occlusive
disease. The costs of routine screening and selective screening were determined with Medicare reimbursement schedules.
Results: The prevalence rate of advanced (80% to 100%) carotid artery stenosis (CAS) was 3.4%, and 18% of the patients
had CAS between 60% and 100%. Advanced peripheral vascular occlusive disease (PVOD; ABI, <0.3) was found in 3% of
the patients, and 12% of the patients had an ABI of less than 0.6. Most patients with advanced CAS (71%) or advanced
PVOD (83%) had clinical indications of their disease. The absence of clinical evidence of disease had a negative predictive
value of 99% for both advanced CAS and PVOD. The cost of routine screening for all patients for advanced CAS was
$5445 per case. Routine screening for severe PVOD costs were $3732 per case discovered. In contrast, the costs for
selective screening for advanced CAS or PVOD in patients with appropriate history or symptoms were $1258 and $785
per case found, respectively.
Conclusion: Routine noninvasive diagnostic testing for the identification of asymptomatic CAS and PVOD in patients
with AAA may not be justified. Preoperative screening is more clearly indicated for patients with AAAs who have clinical
evidence suggestive of CAS or PVOD. (J Vasc Surg 2002;35:754-8.)
The exact role of atherosclerosis in the pathogenesis of
abdominal aortic aneurysms (AAAs) remains controversial.
Yet, there is clear evidence that patients with AAAs may
harbor a significant burden of atherosclerotic occlusive
disease elsewhere. Approximately 60% of patients with
AAAs who underwent evaluation with coronary angiogra-
phy had severe coronary artery disease,1 17% to 21% had
50% carotid artery stenosis (CAS) with duplex scanning
results,2,3 and 20% to 40% had evidence of peripheral
vascular occlusive disease (PVOD).4
Concerns regarding the cost-effectiveness of routine
imaging of all potential atherosclerotic beds raise the issue
of a targeted approach to screening. Although the use of
clinical decision rules may limit the use of high-cost tech-
nologies, some investigators argue for routine screening to
avoid missing potentially surgically correctable lesions (eg,
carotid arterial stenosis) that either alter perioperative risk
or provide long-term benefit to the patient.2 This study is a
retrospective review of diagnostic vascular laboratory and
economic data for the assessment of the cost and usefulness
of routine versus selective use of preoperative screening for
clinically relevant nonaortic atherosclerotic occlusive dis-
ease in patients with AAAs.
METHODS
Patient records and imaging study results were retro-
spectively reviewed for 206 patients who underwent evalu-
ation for AAA repair from January 1995 to October 1998
at the University of Michigan hospital. The characteristics
of these patients were typical of individuals who have AAAs
(Table I). The patients underwent a preoperative work-up
that included abdominal ultrasonographic scan or com-
puted tomographic scan, carotid duplex scan, and lower
extremity arterial Doppler scan studies. Lower extremity
data were not available for 12 of the patients (6%). The
following patients were studied: 189 patients who under-
went repair of AAAs and 17 patients who completed a
preoperative work-up and subsequently did not undergo
operation because of medical comorbidities (n  12),
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death before operation (n  2), aneurysm extent (n  2),
or preoperative cerebrovascular accident (n  1). These
patients represented 74% of all patients who underwent
repair of AAA during the study period. The characteristics
of this population were not significantly different from
patients who did not have complete data available for
review (Table I).
The patients were classified into categories of carotid
arterial disease on the basis of standard duplex ultrasono-
graphic scan imaging results and velocity values.5 The
group with advanced CAS included patients who had po-
tentially operable lesions. Advanced CAS was defined as a
stenosis of 80% to 99% with duplex scan imaging in an
patient who was asymptomatic or as a 60% to 99% stenosis
with duplex scan imaging in a patient with appropriate
symptoms.6-8 In the diagnostic vascular laboratory, valida-
tion study results have confirmed that a stenosis of 80% to
99% with duplex ultrasonographic scan is equivalent to an
angiographic stenosis of 72%. Similarly, a 60% to 80%
stenosis with duplex ultrasonographic scan is equivalent to
a50% stenosis with angiography. CAS of 60% to 79% in a
patient who was asymptomatic was considered important
because of the potential to influence follow-up examina-
tion. However, because this disease did not warrant oper-
ative therapy, it was not considered advanced CAS. Patients
with occluded carotid arteries were included in the ad-
vanced CAS category. However, because they were not
operative candidates and would not benefit from carotid
endarterectomy (CEA), they were not considered to bene-
fit from screening in the cost-effectiveness analysis. Ad-
vanced PVOD was defined as an ankle-brachial index (ABI)
of less than 0.3 or a toe arterial pressure of less than 30 mm
Hg. PVOD, manifested with an ABI of less than 0.6, a toe
pressure of less than 60 mm Hg, or monophasic Doppler
scan signals at both the posterior tibial and dorsalis pedis
arteries, was also reported.
The patients were classified as having clinical indica-
tions for diagnostic screening for occlusive disease on the
basis of the documented history or symptoms recorded in
their medical records. The patients were considered to have
clinical indications of CAS if they had had transient isch-
emic attacks, amaurosis fugax, a completed stroke, or a
history of prior CEA. The following conditions were clini-
cal indications for screening for PVOD: claudication, rest
pain, or history of amputation.
The economic data were derived from Medicare fee
schedules for professional and facility reimbursements in
the State of Michigan for the following procedures by
current procedural terminology codes: 93880 (carotid du-
plex examination), $185; and 93923 (lower extremity
Doppler scan studies), $115. The Medicare reimburse-
ments were used as a proxy for true institutional cost
because they were believed to be more generalized and, as
such, reflected the cost incurred by third-party payers for
patients subjected to preoperative screening. The cost data
were used to calculate the cost per abnormal lesion identi-
fied. As summarized in the Appendix, the cost-effectiveness
ratios for screening and subsequent CEA in patients who
met established operative criteria6-8 were then calculated
with data from previous investigations on symptomatic and
asymptomatic CAS.9,10
Descriptive statistics were calculated with Student t test
and Pearson 2 test for continuous and categoric variables,
respectively. All the analyses were conducted with Stata 6.0
(Stata Corporation, College Station, Tex). This study was
approved by the University of Michigan Institutional Re-
view Board.
RESULTS
The prevalence rate of advanced CAS was 3.4%, which
included four patients (2%) with occluded carotid arteries.
The overall prevalence rate of either advanced CAS or
asymptomatic 60% to 79% stenoses was 18% (Table II). The
prevalence rate of advanced PVOD with an ABI of less than
0.3 was 3%, and 12% of all patients had an ABI of less than
0.6. Evidence of both CAS and PVOD occurred in 6.3% of
the entire series.
Among the patients with advanced CAS, 71% had
reported clinical evidence of disease (Table II). In this
advanced CAS category, the positive predictive value of
clinical indications was 15% and the negative predictive
value was 99% (Table III). The calculated cost for the
identification of a patient with advanced CAS was $5445 if
all the patients were screened (Table IV). If only patients
Table I. Characteristics of 206 patients who underwent
evaluation for abdominal aortic aneurysm repair
Patients subjected to
screening protocol
(mean  SD)
Patients not subjected
to screening protocol
(mean  SD)
No. of patients 206 47
Age (y) 71.6  6.9 70.5  8.4
Male gender 78% 83%
Hypertension 71% 66%
History of angina 53% 13%
Current or former
smoker
97% 78%
AAA size (cm) 5.8  1.3 6.0  1.3
SD, Standard deviation; AAA, abdominal aortic aneurysm.
Table II. Prevalence rate of noncoronary atherosclerotic
disease
Disease category Prevalence Symptomatic
I. Advanced cerebrovascular disease
(symptomatic CAS, 60%;
asymptomatic CAS, 80%)
3.4% 71%
II. All cerebrovascular disease
(any CAS, 60%)
18% 37%
III. Advanced lower extremity
PVOD (ABI, 0.3)
3% 83%
IV. All lower extremity PVOD
(ABI, 0.6)
12% 61%
CAS, Carotid arterial stenosis; PVOD, peripheral vascular occlusive disease;
ABI, ankle-brachial index.
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with clinical indications were screened, the cost per ad-
vanced CAS lesion identified was reduced to $1258. In
contrast, the screening of patients who were asymptomatic
was associated with a cost per advanced CAS lesion identi-
fied of $15,911. The cost of screening patients for any
degree of CAS60% was only $1003 per patient identified.
Only 37% of the patients with CAS 60% had clinical
indications of cerebrovascular disease. Thus, in this series of
patients with AAA, the cost per case of CAS 60% found
was $449 for individuals who were symptomatic and $1326
for those who were asymptomatic.
Most patients (83%) with advanced PVOD had clinical
indications of their disease (Table II). Among the patients
with advanced PVOD, the absence of clinical indications
predicted the absence of severe disease in 99% of the
patients (Table III). The cost of screening all the patients
with AAA for severe PVOD with lower extremity Doppler
scan arterial studies was $3732 per case identified, but the
cost of screening only patients who were symptomatic was
$785 per case identified (Table IV). In contrast, the screen-
ing of patients who were asymptomatic was associated with
a cost of $18,470 per case identified. Clinical evidence of
disease was much less common (61%) when all the patients
with an ABI of less than 0.6 were included with the cost per
case of any PVOD found: $974 for all patients, $280 for
patients with clinical indications, and $2052 for patients
without clinical indications of PVOD.
DISCUSSION
AAA and atherosclerotic occlusive disease frequently
coexist. In this study, 18% of the patients had evidence of
CAS and 12% had PVOD that affected their lower extrem-
ities. However, the incidence rate of advanced occlusive
disease was only 3.4% and 3.1% for CAS and PVOD,
respectively. Furthermore, only 1.4% of the patients had
CAS that would justify operative intervention because the
remainder of the patients had already had a carotid arterial
occlusion. Furthermore, most patients with advanced CAS
(71%) and PVOD (83%) were either symptomatic or had a
history suggestive of cerebrovascular or lower extremity
disease. The absence of clinical indications of CAS or
PVOD excluded advanced disease in more than 99% of the
patients. In this regard, screening all patients for evidence
of occlusive disease is resource intensive. The cost of screen-
ing, per patient with advanced disease identified, was ap-
proximately $16,000 for CAS and $18,500 for PVOD
among patients who were asymptomatic.
The incidence rate of occlusive disease in this series of
patients with AAAs is concordant with the rates of previous
investigations. Cahan and colleagues2 reported an inci-
dence rate of CAS50% in 17% of patients who underwent
AAA repair and an incidence rate of CAS 70% in 9%.
Similarly, Cheng and colleagues11 identified CAS70% in
8.9% of patients with AAAs, and Deville and associates12
reported high-grade (70%) internal CAS in 2.1% of pa-
tients. Unfortunately, the prevalence of clinical indications
of CAS was not described in these former reports. The
incidence rate of clinical or radiographic evidence of occlu-
sive disease in the report from Johnston and Scobie13 of
666 nonruptured AAAs was 22.3% in the aortoiliac region
and 25.6% in the femoral-popliteal arteries. Other studies
with routine angiography before AAA have shown occlusive
lesions in 28% of iliac arteries, 12.5% of femoral arteries, and
12.5% of popliteal arteries.14 Overall, 67% of the occlusive
lesions identified in the later series were clinically evident.14
Although there is no evidence that preoperative CEA
reduces the risk of perioperative stroke, prophylactic CEA
has been shown to be cost-effective in previous decision
Table III. Diagnostic value of clinical indications
Occlusive disease category Sensitivity Specificity
Positive predictive
value
Negative predictive
value
I. Advanced cerebrovascular disease (symptomatic CAS,
60%; asymptomatic CAS, 80%)
71% 85% 15% 99%
II. All cerebrovascular disease (any CAS, 60%) 37% 88% 41% 86%
III. Advanced lower extremity PVOD (ABI, 0.3) 83% 85% 15% 99%
IV. All lower extremity PVOD (ABI, 0.6) 61% 88% 41% 94%
CAS, Carotid arterial stenosis; PVOD, peripheral vascular occlusive disease; ABI, ankle-brachial index.
Table IV. Cost of screening in patients with abdominal aortic aneurysms
Occlusive disease category
All patients
(cost/case
identified)
Patients with history
or symptoms (cost/
case identified)
Patients without history
or symptoms (cost/case
identified)
I. Advanced cerebrovascular disease (symptomatic CAS,
60%; asymptomatic CAS, 80%)
$5445 $1258 $15,911
II. All cerebrovascular disease (any CAS, 60%) $1003 $449 $1326
III. Advanced lower extremity PVOD (ABI, 0.3) $3732 $785 $18,470
IV. All lower extremity PVOD (ABI, 0.6) $974 $280 $2052
CAS, Carotid arterial stenosis; PVOD, peripheral vascular occlusive disease; ABI, ankle-brachial index.
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models. For an estimate of the potential benefit of routine
screening, the cost-effectiveness of various CAS screening
protocols and subsequent CEA then was determined for
patients who met established operative criteria (Appendix
1). The screening of all patients with AAAs for advanced
CAS and the operation of appropriate candidates would
result in an additional 0.75 years of life for the population
included in this study. The incremental cost of screening all
patients and operating on appropriate candidates when
compared with no screening and treatment of patients with
symptomatic stroke was estimated to be $44,324 (Appen-
dix 2). Therefore, the cost per life year saved for universal
screening was estimated to be $58,979. The screening of
patients who were asymptomatic was not cost-effective,
being $135,449 per life year saved. The screening of pa-
tients with symptomatic cerebrovascular disease, estimated
to cost $20,744 per life year saved, is cost-effective, given
an acceptable threshold for cost-effectiveness of $50,000
per life saved.
The appropriate use of routine screening for extraaortic
occlusive disease before AAA surgery continues to be a
controversial subject. However, recent consensus panels
and large cohort studies have argued for a more focussed
use of preoperative imaging evaluation. For example, inva-
sive and noninvasive coronary imaging is now recom-
mended only for patients with documented clinical risk
factors that suggest correctable coronary disease.15 Simi-
larly, routine peripheral angiography has not been shown to
improve the care of patients who undergo AAA repair.13,16
Minimally invasive examinations make universal screening
of patients with AAAs a theoretically attractive option, but
the value of this testing is unclear. Although CEA may be
protective before AAA,17 the severity of CAS in patients
with AAA has not been found to correlate with stroke risk
in large series.2,18 Furthermore, in patients with asymp-
tomatic PVOD, only the identification of unknown iliac
artery occlusion has been shown to change the operative
management of an AAA.13 Finally, the use of screening for
asymptomatic CAS has been addressed in a well-con-
structed Markov model by Yin and Carpenter.19 In this
study, the authors found that screening patients who were
asymptomatic was only cost-effective if the prevalence rate
of lesions that meet Asymptomatic Carotid Atherosclerosis
Study criteria exceeds 4.5%. According to their analysis, at a
prevalence rate of 3%, the cost per quality-adjusted life year
was $102,160. In this series, the incidence rate of asymp-
tomatic high-grade stenosis that met Asymptomatic Ca-
rotid Atherosclerosis Study criteria for operation was only
1.4%, which suggests that routine screening is not likely to
be cost-effective.
This study has certain limitations. First, it is a retrospec-
tive examination, and patients who were symptomatic may
not have been appropriately identified in the medical
record. However, this is more likely to diminish the value of
symptoms as a predictive factor. Furthermore, the surgeons
were not blinded to the results of the noninvasive studies.
Thus, positive studies may have benefits not accounted for
in the cost-effectiveness analysis results, such as the sugges-
tion of the need for additional diagnostic studies. However,
given the low incidence of disease in patients without
clinical indications for testing, it appears unlikely that re-
stricting screening would have significant adverse results.
Second, the economic costs include only the cost of diag-
nosis and, therefore, underestimate the true cost of univer-
sal screening and subsequent patient care. The true cost of
universal screening should actually include the cost of
further evaluation and treatment of the patients with false-
positive tests, such as arteriography in patients with abnor-
mal lower extremity Doppler scan study results. Finally,
there may be medicolegal reasons for additional diagnostic
procedures. However, because preoperative treatment does
not seem to correlate with improved outcomes, this poten-
tial benefit is unlikely to be realized.
This investigation suggests that preoperative noninva-
sive imaging in patients who undergo AAA should be
limited to those patients with clinical indications of under-
lying arterial occlusive disease. Routine screening appears
to be neither efficient nor clinically indicated in patients
with AAA with asymptomatic CAS or PVOD. In contrast,
those patients with a history or symptoms that suggest CAS
or PVOD warrant an evaluation before aortic surgery.
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Appendix 1.
Cost-effectiveness of screening for carotid artery steno-
sis was calculated with data from three sources. Prevalence
rate of asymptomatic disease in patients with and without
clinical manifestations was calculated from this series. There
were no patients with active transient ischemic attacks or
mild, recently completed strokes screened in this popula-
tion. Thus, the prevalence rate of patients with symptom-
atic disease that met North American Symptomatic Carotid
Endarterectomy Trial criteria was zero. The cost of screen-
ing was determined to be the Medicare reimbursement for
a single duplex ultrasound scan ($185). This cost, in fact,
likely underestimates the cost of false-positive tests that
incur the cost of further work-up with angiography or the
morbidity of an unnecessary operation in centers that op-
erate solely on the basis of duplex scan results. Finally, the
incremental cost of CEA when compared with medical
management was determined from the literature. Cronen-
wett and colleagues10 determined that operative therapy
exceeded medical therapy by $2041 per patient. This ex-
penditure was associated with a quality-adjusted life year
(QALY) increment of 0.25 QALYs per patient treated. As
summarized in the previous table, the cost-effectiveness of
the screening for each group was the sum of the cost of
screening and the cost of treatment for patients identified as
having disease, divided by the total increase in QALYs
associated with treatment.
Appendix 2. Calculation of cost-effectiveness of screening for carotid artery stenosis
All patients
Patients with clinical
manifestations
Patients without clinical
manifestations
No. of patients 206 34 172
No. of cases of advanced CAS 3 2 1
Cost of screening 206  $185  $38,111 34  $185  $6290.29 172  $185  $31,821.47
Incremental cost of treatment 3  $2041  $6123 2  $2041  $4082 1  $2041  $2041
Total cost $44,234.75 $10,372.29 $33,862.46
QALY gain 3  0.25  0.75 2  0.25  0.50 1  0.25  0.25
Cost per QALY $58,979.68 $20,744.58 $135,449.83
Data derived from Cronenwett JL, Birkmeyer JD, Nackman GB, Fillinger MF, Bech FR, Zwolak RM, et al. Cost-effectiveness of carotid endarterectomy in
asymptomatic patients. J Vasc Surg 1997;25:298-309.
QALY, Quality-adjusted life year.
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